| |
| |
| Transfection |  |
|
| |
|
| |
| The application of systems biology and multidisciplinary approaches require that cells and model systems display in vivo like cellular functionality. This means that the future of cell transfection is in using primary cell types, and that transfecting these physiologically relevant cell types is typically a very difficult task using traditional methods. Additionally, when using relevant cell lines as model systems, the critical issues are to achieve reproducibly efficient transfection with high levels of viability while matching throughput capability with the number of transfections required at each project phase – from proof of concept, through to scale-up and screening-like approaches. With the Amaxa™ Nucleofector™ Technology primary cells and stem cells, as well as cell lines, can be consistently transfected at high efficiency. |
| |
Developed in 1998, the Amaxa™ Nucleofector™Technology was introduced to the research market in 2001 as the first efficient non-viral transfection method for primary cells and hard-to-transfect cell lines. Since then the technology has evolved through constant innovation.
The technology is lifted to the next dimension with its two new platforms: |
| |
 | The 4D-Nucleofector™ System offering highest flexibility for numerous transfection applications |
|
| The 384-well Nucleofector™ System enabling Nucleofection™ in 384-well format |
|
| |
| |
| The Principle |
| |
| Nucleofection™ is a technology based on the momentary creation of small pores in cell membranes by applying an electrical pulse. The comprehensive way in which Nucleofector™ Programs and cell-type specific solutions are developed enables nucleic acid substrate delivery not only to the cytoplasm, but also through the nuclear membrane and into the nucleus. This allows for high transfection efficiencies up to 99% and makes the transfection success independent from cell proliferation. |
| |
| |
Components of the Nucleofector™ Technology
The Nucleofector™ Technology relies on the combination of a Nucleofector™ Device and cell specific Nucleofector™ Kits:
|
| |
| The Nucleofector™ Device delivers unique electrical parameters. The electrical settings are pre-programmed for each optimized cell type and can be selected via the device or PC software. We offer three different device platforms plus an add-on device (see table below)
|
|
| The Nucleofector™ Kitscontain a specific Nucleofector™ Solution and Supplement, specified cuvettes, pipettes, and the pmaxGFP™ Control Vector. All Nucleofector™ Solutions provide a protective environment that allows for high transfection efficiency and cell viability, while helping to maintain physiologically relevant cellular functions. A collection of Nucleofector™ Kits with optimized protocols for primary cells and cell lines is available
|
|
| Besides providing optimal Nucleofection™ Conditions, Amaxa™ Optimized Protocols offer comprehensive guidance, including tips for cell sourcing, passage, growth conditions and media, and post transfection culture
|
|
| |
 |
| |
| |
| Click Here to Browse Products |
| |
